Predictors of Cognitive Decline in Normal Aging - Full Text View

Purpose

The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.

Condition	Phase
Alzheimer Disease Dementia	Phase II

Genetics Home Reference related topics:

Alzheimer disease Dementia

MedlinePlus related topics:

Alzheimer's Disease Dementia

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Longitudinal, Case Control, Prospective Study

Official Title:	Predictors of Cognitive Decline in Normal Aging

Further study details as provided by National Institute on Aging (NIA):

Estimated Enrollment:	170
Study Start Date:	September 2003
Estimated Study Completion Date:	August 2008

Detailed Description:

Studies of normal aging and mild cognitive impairment (MCI) show that loss of neurons and reduction in size of the hippocampal part of the brain predict a person's conversion from MCI to Alzheimer's disease (AD). Increases in tangle-related abnormal tau proteins, specifically P-tau231, also appear to be related.

This study will collect neuropsychological data, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) from volunteer participants to measure the relationship between changes in brain volume, CSF levels, and memory performance.

From the data researchers hope to develop an early diagnostic test for AD.

The study will include 170 participants between the ages of 60 and 80 years, some normal, some with MCI, some with mild AD, and some with frontotemporal dementia. After initial screening of volunteers, the researchers will give participants a complete baseline exam and 24-month follow-up exams over a period of five years.

Eligibility

Ages Eligible for Study:	60 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Males and females, from all racial and ethnic categories between the ages of 60-80 years of age, with English as their first language.
Residents of the New York City metropolitan area.
Minimum of 12 years of education.
Participants will be grouped according to the following classifications: normal aging, mild cognitive impairment (MCI), Alzheimer's disease (AD), or frontotemporal dementia (FTD).
Participants will agree to ApoE genotyping and DNA banking.

Exclusion Criteria:

Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, lacunar infarcts, seizures, mental retardation or serious neurological disorder.
Significant history of alcoholism or drug abuse.
History of psychiatric illness (e.g., schizophrenia, mania or depression).
Any focal signs or significant neuropathology.
A score of 4 or greater on the Modified Hachinski Ischemia Scale suggesting cerebrovascular disease.
A total score of 16 or more on the Hamilton Depression Scale to exclude possible cases of primary depression.
Evidence of clinically relevant and uncontrolled hypertensive, cardiac, pulmonary, vascular, metabolic or hematologic conditions.
Physical impairment of such severity as to adversely affect the validity of psychological testing.
Hostility or refusal to cooperate.
Any prosthetic devices (e.g., pacemaker or surgical clips) that could be affected by the magnetic field employed during MRI imaging.
History of familial early onset dementia.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00094939

Contacts


Contact: Kenneth E. Rich	212-263-7563	kenneth.rich@med.nyu.edu

Locations


United States, New York
	Center for Brain Health, Silberstein Institute, New York University School of Medicine	Recruiting
	New York City, New York, United States, 10016
	Contact: Kenneth E. Rich 212-263-7563 kenneth.rich@med.nyu.edu

Sponsors and Collaborators

National Institute on Aging (NIA)

Investigators


Principal Investigator:	Mony J. de Leon, Ed.D.	Center for Brain Health, Silberstein Institute

More Information

Publications:

de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBernardis J, Kerkman D, Qadri F, Gary A, Lesbre P, Wisniewski T, Poirier J, Davies P. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002 Nov 29;333(3):183-6.

Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002 Aug 27;59(4):627-9.

Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000 Jan;57(1):100-5.

Study ID Numbers:	IA0056, R01 AG12101
First Received:	October 28, 2004
Last Updated:	July 11, 2007
ClinicalTrials.gov Identifier:	NCT00094939
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Aging (NIA):

mild cognitive impairment

Alzheimer disease

magnetic resonance imaging

CSF tau protein

Hippocampus

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders

Alzheimer Disease

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Dementia

Cognition Disorders

Delirium

Additional relevant MeSH terms:

Mental Disorders

Nervous System Diseases

Tauopathies

ClinicalTrials.gov processed this record on July 03, 2008

Sponsored by:	National Institute on Aging (NIA)
Information provided by:	National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:	NCT00094939